Stock Taper Q4 Revenue: Increased by over 6% year-over-year to $1.23 billion.
Adjusted EBITDA: Decreased by 10% to $104.7 million from $116.0 million in the prior year.
Earnings per Share (EPS):
From continuing operations: $0.16, compared to a loss of $0.19 in the prior year.
Adjusted EPS: $0.16, down from $0.18.
Full Year 2025 Revenue: Grew over 5% to approximately $5.4 billion.
Full Year Adjusted EBITDA: $493.2 million with a 9% margin, down from $510.4 million and a 9.8% margin in 2024.
Debt: $1.8 billion outstanding with a net leverage ratio of 3.67x.
Cash Flow from Operations: $64.3 million for the quarter.
Expansion: Added 150 inpatient rehabilitation beds in Q4, totaling 212 for the year. Future plans include adding 399 beds across 2026 and 2027.
New Partnerships: Opened new rehabilitation hospitals in collaboration with Baylor Scott & White Health and CoxHealth.
Dividend: A cash dividend of $0.0625 per share was approved, payable in March 2026.
2026 Revenue Guidance: Expected to be between $5.6 billion and $5.8 billion.
Adjusted EBITDA Guidance: Projected in the range of $520 million to $540 million.
EPS Guidance: Anticipated to be between $1.22 and $1.32.
Capital Expenditures: Expected to be between $200 million and $220 million.
Decline in Adjusted EBITDA: Primarily due to increased health insurance expenses and higher-cost claimants.
Outpatient Rehab Division Weakness: Adjusted EBITDA fell to $11.2 million, with a margin decline to 3.4%. Contributing factors included lower net revenue per visit due to reduced Medicare reimbursement and an unfavorable payer mix.
Labor Challenges: Staffing issues in certain markets have contributed to softness in outpatient performance.
Increased Health Costs: Approximately $15 million impact from health insurance expenses across the company, with outpatient being particularly affected.
Health Costs Breakdown: The outpatient division faced approximately $5 million in health insurance expenses and $6 million in variable discounts, totaling around $11 million impacting profitability.
Outlook for Outpatient Rehab: Management expressed cautious optimism for improvement in 2026, expecting the issues to be one-time occurrences.
Market Conditions: Some softness in outpatient markets attributed to competitive pressures and staffing challenges.
Regulatory Changes: Anticipated 2% increase in Medicare rates for 2026 may positively impact margins.
Share Repurchase Strategy: Currently on hold due to the ongoing review of a take-private proposal from the Executive Chairman. This summary encapsulates the key financial metrics, strategic initiatives, forward-looking guidance, and challenges faced by Select Medical Holdings Corporation as discussed in the Q4 2025 earnings call.
SOURCE: Q4 2025 EARNINGS CALL TRANSCRIPT